Understanding biomarkers and outcomes in Charcot-Marie-Tooth disease
Official title: Longitudinal Biomarkers With Selected Outcome Measures In CMT
Run by University Medical Center Goettingen · NCT06794489 · Data updated 2026-11-12
This study is trying to see how Charcot-Marie-Tooth disease type 1A changes over time by looking at blood and skin samples from patients and healthy people to find better ways to track the disease and develop new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen, Lower Saxony) |
| Status | Recruiting |
| Started | November 6, 2024 |
| Main results expected | July 5, 2026 |
| Study ends | July 5, 2026 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT06794489 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 65 with a clinical diagnosis and genetic confirmation of CMT.
✕Probably not a fit
Patients with other significant neurological or psychiatric disorders, or those who are pregnant or breastfeeding, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the progression of Charcot-Marie-Tooth disease type 1A (CMT1A) by identifying risk factors that influence the disease course. Over five years, researchers will analyze biomarkers from blood and skin samples of CMT patients, alongside a control group of healthy volunteers, to validate sensitive outcome measures. The study seeks to document symptom variability and disease dynamics, which could support the development of novel therapies for this hereditary neuropathy. By correlating molecular analyses with clinical data, the research hopes to establish practical biomarkers for monitoring disease severity and progression.
Why it matters
Potential benefit: If successful, this study could lead to the identification of reliable biomarkers that improve monitoring and treatment outcomes for patients with CMT1A.
How similar studies have gone: While there have been preliminary studies exploring biomarkers in CMT, this approach is novel and aims to establish practical biomarkers for clinical use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical CMT Diagnosis / Anamnestically Healthy Control Group * Genetic confirmation of CMT in adult patients * Ability to achieve the outcome measure at baseline * Age between 18 and 65 years * Capacity of all study participants to consent and signed informed consent, including patient or participant information and consent form Exclusion Criteria: * Pregnancy or breastfeeding period * Other relevant neurological or psychiatric disorders, acute or in the past history * Presence of a serious previous internal disease
Where it's running
-
University Medical Centre
Göttingen, Lower Saxony, Germany Recruiting
Study contacts
- Study coordinator: Michael W Sereda, Prof. MD
- Email: sereda@mpinat.mpg.de
- Phone: +49 551 3964162
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multi-omic search for early biomarkers in CMT1A
This project will test whether blood-based molecular signatures and qMRI measures in children and young adults with CMT1A can predict how the disease will progress.
-
Autonomic problems in Charcot–Marie–Tooth disease
This study will test how common and how severe autonomic (automatic nervous system) symptoms are in adults aged 18–65 with genetically confirmed Charcot–Marie–Tooth disease compared with healthy volunteers.
-
Tremor in Charcot–Marie–Tooth disease
Try to characterize tremor in adults with Charcot–Marie–Tooth (CMT) disease using surface electromyography, accelerometers, a clinical exam and questionnaires to see how tremor affects daily life.
-
Nerve function and structure in CMT, anti‑MAG neuropathy, and CIDP
This project will test nerve‑conduction, axonal‑excitability, skin biopsy, and ultrasound measures in adults with CMT, CIDP, or anti‑MAG neuropathy to see if they better describe nerve function and structure.
-
Ankle-foot braces versus surgery to improve walking and balance in CMT
This will test whether ankle-foot braces or surgical correction better improve walking, balance, and mobility for people aged 12 to 75 with genetically confirmed Charcot–Marie–Tooth disease.
-
8-week lower-limb resistance program for young people with Charcot–Marie–Tooth disease
This program will test whether 8 weeks of supervised lower-limb resistance exercises help improve muscle quality, functional ability, and quality of life in 15–29 year olds with and without Charcot–Marie–Tooth disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.